The vaccine showed promising results in clinical ... could significantly reduce the incidence of serious pneumococcal diseases in adults. This is particularly important for older adults and ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, ...

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults “Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are ...

Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

Vaxcyte said its vaccine covers serotypes involved in around 95% of invasive pneumonia disease (IPD) cases in adults 50 and older in the US. It expects the pneumococcal vaccine market to reach a ...

Early protection for young and very young children against pneumococcus is not only about protecting the children themselves but also about limiting transmission, contributing to the protection of the ...

[48] This study determined that PPV23 vaccination was significantly effective in preventing IPD in adults. In ten prospective clinical trials that included 35,483 patients, the pooled estimate of ...